Dianthus Therapeutics (NASDAQ:DNTH) Stock: Insider Ryan Savitz Sells 17,724 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 17,724 shares of the stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $90.56, for a total value of $1,605,085.44. Following the transaction, the executive vice president owned 29,276 shares of the company’s stock, valued at $2,651,234.56. This represents a 37.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Ryan Savitz also recently made the following trade(s):

• On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.03, for a total transaction of $274,051.32.
• On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.54, for a total transaction of $9,118,555.02.
• On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.14, for a total transaction of $230,848.54.

Dianthus Therapeutics Stock Down 0.7%

Dianthus Therapeutics stock opened at $91.81 on Friday. Dianthus Therapeutics, Inc. has a 52-week low of $34.29 and a 52-week high of $117.88. The firm’s fifty day moving average is $88.45 and its 200 day moving average is $86.56. The company has a market cap of $5.17 billion, a price-to-earnings ratio of -23.01 and a beta of 1.47.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 19.68%. The business had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $0.46 million. On average, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. ABS Investment Management LLC purchased a new stake in shares of Dianthus Therapeutics in the second quarter valued at $194,960,000. EFG International AG bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth about $49,000. GAMMA Investing LLC lifted its holdings in shares of Dianthus Therapeutics by 83.6% in the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock worth $49,000 after acquiring an additional 254 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Dianthus Therapeutics by 23.6% in the 3rd quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock worth $60,000 after acquiring an additional 129 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter worth about $93,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Dianthus Therapeutics

Investors following DNTH have been watching these headlines:

• Positive Sentiment: Analyst coverage is broadly favorable. A report highlights bullish views on DNTH, and HC Wainwright reiterated a Buy rating with a $158 price target and a bullish FY2026 earnings outlook. The available FY2026 report does not detail the estimate or its rationale. Article: Analysts Are Bullish on These Healthcare Stocks Article: HC Wainwright Has Bullish Estimate for DNTH FY2026 Earnings
• Negative Sentiment: EVP Ryan Savitz sold 124,042 shares from November 9–12 for about $11.2 million, sharply reducing his reported stake. The filings do not state why he sold, but the scale of the transactions may concern investors. Article: Dianthus Therapeutics EVP Sells Shares

Analysts Set New Price Targets

Several research analysts recently commented on DNTH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. Citigroup started coverage on Dianthus Therapeutics in a research note on Friday, September 4th. They set a “buy” rating and a $156.00 price objective on the stock. Wedbush upped their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. HC Wainwright restated a “buy” rating and set a $158.00 price objective on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $134.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $128.77.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.